AstraZeneca Submits EUA for COVID Antibody Prophylaxis
October 5, 2021
AstraZeneca published a press release today stating that their long-acting antibody (LAAB) combination, AZD7442, has been shown to reduce the risk of symptomatic Covid-19 by 77% in a clinical trial. The trial included many participants who had medical conditions placing them at greater risk of severe illness and those who had not been producing sufficient antibodies after vaccination.
AstraZeneca has requested that the FDA grant emergency authorization for this new treatment. If this happens, it will be the first treatment of its kind available in the United States.
AZD7442 differs from the Regeneron antibody treatment because it is meant to prevent someone from becoming infected with COVID-19, as opposed to treating someone who has already been infected with COVID-19. The company stated that this treatment could be used in conjunction with vaccines, benefitting those with weaker immune systems, including those who are immunocompromised.